# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Data, from a post hoc analysis of the randomized, placebo-controlled, double-blind phase 2/3 study of oral opaganib in COVID-19...
Orphan Drug designation provides for a seven-year marketing exclusivity period should opaganib be approved in neuroblastoma and...
The commercial launch of Talicia in the UAE triggers RedHill's eligibility for additional potential milestone payments, min...
RedHill Biopharma released study results showing opaganib's potential in treating Type 2 diabetes and obesity. The drug'...
RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today...